1383446-21-6

Upstream product

• 1480-65-5 2-fluoro-5-chloropyridine 
• 882679-90-5 5-chloro-2-fluoropyridine-3-carbaldehyde 
• 76-09-5 2,3-dimethyl-2,3-butane diol 

Downstream Products

• 1240725-66-9 5-chloro-1H-pyrazolo[3,4-b]pyridine 
• 1352395-64-2 5-chloro-3-iodo-1H-pyrazolo[3,4-b]pyridine 
• 1383446-23-8 5-chloro-3-iodo-1-trityl-1H-pyrazolo[3,4-b]pyridine 
• 1383446-24-9 5-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl-2-yl)-1-trityl-1H-pyrazolo[3,4-b]pyridine 
• 1383446-29-4 5-chloro-3-(5-fluoro-4-(methylthio)pyrimidin-2-yl)-1-trityl-1H-pyrazolo[3,4-b]pyridine 
• 1383446-31-8 5-chloro-3-(5-fluoro-4-(methylsulfinyl)pyrimidin-2-yl)-1-trityl-1H-pyrazolo[3,4-b]pyridine 

Relevant academic research and scientific papers

BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT， AMELIORATION OR PREVENTION OF INFLUENZA

The present invention relates to a compound having the formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing influenza.

PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF

Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.